CHPA honors Dr. Doug Bierer with William Cooley Regulatory & Scientific Affairs Career Achievement Award

BETHESDA, Md. – The Consumer Healthcare Products Association (CHPA) announced that Dr. Doug Bierer has been honored with its prestigious William Cooley Regulatory & Scientific Affairs Career Achievement Award in recognition of his exceptional service and contributions to the consumer healthcare products industry.

The 2024 William Cooley Regulatory & Scientific Affairs Career Achievement Award was presented to Bierer by Kenvue's senior director of Regulatory Affairs for Self-Care and Chair of CHPA's Regulatory & Scientific Affairs Committee (RSAC) Glen Murphy during CHPA’s annual RSQ Conference on Sept. 17 at the Bethesda North Marriot Hotel and Conference Center in Maryland.

Previously known as the Regulatory & Scientific Affairs Career Achievement Award, this marks the first year the award has been presented under its new name, celebrating the enduring legacy of its namesake in honor of Dr. William Cooley’s more than 40 years of industry contributions, which helped build the Over-The-Counter (O-T-C) Monograph system we have today. This honor, awarded annually at the association’s Regulatory, Scientific & Quality Conference (RSQ), recognizes individuals who have created a long-lasting impact in support of public health via self-care.

This year’s recipient, Dr. Doug Bierer, has been an outstanding industry leader for more than 36 years, making exceptional strides across regulatory matters that led to increased access of consumer health care products during his distinguished career at Procter & Gamble (P&G). Notably, his leadership in the Rx-to-OTC switch of omeprazole revolutionized the landscape of self-care, providing consumers greater access to a vital self-treatment option. Since retiring from P&G, Bierer continued to shape the regulatory environment through his role as Vice President of Regulatory & Scientific Affairs at CHPA and as a consultant for industry issues related to toxicology, regulatory affairs, and clinical development.

“We are honored to present this award to Doug today, whose work has not only transformed the OTC regulatory landscape but has set a high standard for our industry,” said CHPA senior vice president of Regulatory & Scientific Affairs Mike Bailey. “The renaming of this award allows us to honor the legacy of industry pioneers alongside extraordinary leaders like Doug, all who serve as inspiration to today’s generation of regulatory professionals and generations to come. I extend my sincere gratitude to Doug for his nearly four decades of contributions to consumer healthcare and congratulate him for receiving this well-deserved award.”